DexTech Medical informs about the myeloma study, the first patient is treated
The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge.
The Phase 1 study investigates the efficacy of OsteoDex in patients with progressive multiple myeloma (MM). The first patient is treated during week 50 at Karolinska University Hospital in Huddinge. The study includes a total of 20 patients and will initially be conducted at three hospitals in Sweden: Karolinska University Hospital Huddinge, Uddevalla Hospital and Södersjukhuset in Stockholm. The treatment lasts for a total of 14 weeks with 2 doses per month. Three dose levels are being studied. The Principal Investigator (PI) is Dr Katarina Uttervall, MD, PhD, Department of Hematology/HERM, Karolinska University Hospital Huddinge. Analysis of biomarkers takes place at the Central Laboratory, Karolinska University Hospital Solna, NKS. Inclusion criteria include adult MM patients with relapsed (progressive) refractory disease, who received 1-5 prior lines of therapy. The primary objective is to confirm safety and tolerability and with the secondary objective to determine treatment response. Biochemical markers are continuously analyzed, and the first assay results are expected in Q1-24.
The study is expected to be completed in Q4, 2024.
The work to seek partnerships regarding continued clinical development of OsteoDex - mCRPC towards phase 3 - is ongoing. The Company's synthesis patent application, filed with the European Patent Office (EPO.Org) in October -23, is of great importance for the Company's opportunities for partnership as well as positive results from the Company's MM study. The conditions for the patent application to be granted are good, resulting in market exclusivity until 2044. Without prejudging the results from the MM study, Osteodex's positive effect on bone-degrading bone cells and the absence of serious side effects are well documented and will probably be confirmed in the MM study as well.
For more information about DexTech, please contact:
Gösta Lundgren – CFO
DexTech Medical AB
Phone: +46 (0) 707104788
E-mail: [email protected]
This information is information that DexTech Medical AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on December 13, 2023.
DexTech Medical AB is a Swedish research company that, based on its technology platform, has developed four drug candidates that are protected by patents. The main candidate is OsteoDex for the treatment of castration-resistant prostate cancer (CRPC) with bone metastases. A successful clinical phase II study has been conducted with OsteoDex where the results show high tolerability with mild side effects and treatment effect on patients who fail on existing drugs. DexTech's goal is to out-license each drug candidate no later than after completion of the phase II study. DexTech Medical AB is listed on Spotlight Stock Market.
